ONTX insider filings
Onconova Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-03-15. Screen ONTX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ONTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Onconova Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-03-15 | 4 | Guerin Mark Patrick — CFO AND COO | Option exercise (M): 8,666 · Tax withholding (F): 2,591 @ $0.90 · Option exercise (M): 8,666 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, Director | Option exercise (M): 23,111 · Tax withholding (F): 8,727 @ $0.90 · Option exercise (M): 23,111 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Guerin Mark Patrick — CFO AND COO | Option exercise (M): 6,900 · Tax withholding (F): 2,443 @ $0.67 · Option exercise (M): 6,900 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, Director | Option exercise (M): 21,320 · Tax withholding (F): 9,212 @ $0.67 · Option exercise (M): 21,320 (derivative) @ $0 | EDGAR |
| 2023-10-27 | 4 | Moyo Victor M — CHIEF MEDICAL OFFICER | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | Shoemaker Mary Teresa — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | STOVER JACK E — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | Atadja Peter — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | Clarke Trafford — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | MEHTA VIREN — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | GROOPMAN JEROME — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | MARINO JAMES J — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2023-08-04 | 4 | Guerin Mark Patrick — CFO AND COO | Option exercise (M): 4,750 · Tax withholding (F): 1,422 @ $1.02 · Option exercise (M): 4,750 (derivative) @ $0 | EDGAR |
| 2023-08-04 | 4 | Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, Director | Option exercise (M): 12,567 · Tax withholding (F): 4,744 @ $1.01 · Option exercise (M): 12,567 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Guerin Mark Patrick — CFO AND COO | Option exercise (M): 5,500 · Tax withholding (F): 1,575 @ $1.14 · Option exercise (M): 5,500 (derivative) @ $0 | EDGAR |
| 2023-03-14 | 4 | Guerin Mark Patrick — CFO AND COO | Grant/award (A): 79,000 (derivative) @ $0 · Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2023-03-14 | 4 | Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, Director | Grant/award (A): 207,000 (derivative) @ $0 · Grant/award (A): 69,333 (derivative) @ $0 | EDGAR |
| 2023-03-14 | 4 | Gelder Mark S. MD — CHIEF MEDICAL OFFICER | Grant/award (A): 62,000 (derivative) @ $0 · Grant/award (A): 20,667 (derivative) @ $0 | EDGAR |
| 2023-02-08 | 4 | Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, Director | Option exercise (M): 21,320 · Tax withholding (F): 6,977 @ $1.36 · Option exercise (M): 21,320 (derivative) @ $0 | EDGAR |
| 2023-02-08 | 4 | Gelder Mark S. MD — CHIEF MEDICAL OFFICER | Option exercise (M): 5,833 · Tax withholding (F): 1,242 @ $1.36 · Option exercise (M): 5,833 (derivative) @ $0 | EDGAR |
| 2023-02-08 | 4 | Guerin Mark Patrick — CFO AND COO | Option exercise (M): 6,900 · Tax withholding (F): 1,785 @ $1.36 · Option exercise (M): 6,900 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | Clarke Trafford — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | Atadja Peter — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-08-19 | 4 | STOVER JACK E — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2022-08-19 | 4 | MARINO JAMES J — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2022-08-19 | 4 | MEHTA VIREN — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2022-08-19 | 4 | Shoemaker Mary Teresa — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2022-08-19 | 4 | GROOPMAN JEROME — Director | Grant/award (A): 66,468 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | Guerin Mark Patrick — CFO AND COO | Option exercise (M): 4,750 · Tax withholding (F): 1,355 @ $1.32 · Option exercise (M): 4,750 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | Gelder Mark S. MD — CHIEF MEDICAL OFFICER | Option exercise (M): 4,650 · Tax withholding (F): 1,135 @ $1.32 · Option exercise (M): 4,650 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, Director | Option exercise (M): 12,566 · Tax withholding (F): 4,562 @ $1.32 · Option exercise (M): 12,566 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Guerin Mark Patrick — COO and CFO | Grant/award (A): 50,250 (derivative) @ $0 · Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2022-02-09 | 4 | Gelder Mark S. MD — Chief Medical Officer | Grant/award (A): 51,750 (derivative) @ $0 · Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2022-02-09 | 4 | Fruchtman Steven M — President, Chief Executive Off, Director | Grant/award (A): 191,880 (derivative) @ $0 · Grant/award (A): 63,960 (derivative) @ $0 | EDGAR |
| 2022-02-09 | 4 | OLER ABRAHAM N. — SVP Corp Dev & Gen Counsel | Grant/award (A): 54,050 (derivative) @ $0 · Grant/award (A): 17,633 (derivative) @ $0 | EDGAR |
| 2022-02-09 | 4 | Guerin Mark Patrick — Chief Financial Officer | Grant/award (A): 62,100 (derivative) @ $0 · Grant/award (A): 20,700 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | OLER ABRAHAM N. — SVP Corp Dev & Gen Counsel | Purchase (P): 1,500 @ $1.67 | EDGAR |
| 2022-01-24 | 4 | OLER ABRAHAM N. — SVP Corp Dev & Gen Counsel | Purchase (P): 1,500 @ $2.02 | EDGAR |
| 2022-01-18 | 4 | OLER ABRAHAM N. — SVP CORP DEV & GEN COUNSEL | Purchase (P): 1,500 @ $2.20 | EDGAR |
| 2022-01-10 | 4 | OLER ABRAHAM N. — SVP Corp Dev & Gen Counsel | Purchase (P): 1,500 @ $2.39 | EDGAR |
| 2021-11-23 | 4 | OLER ABRAHAM N. — SVP CORP DEV & GEN COUNSEL | Purchase (P): 1,000 @ $3.16 | EDGAR |
| 2021-11-19 | 4 | OLER ABRAHAM N. — SVP Corp Dev & Gen Counsel | Option exercise/expiry (X): 5,000 @ $3 · Option exercise/expiry (X): 5,000 (derivative) @ $0 | EDGAR |
| 2021-09-29 | 4 | OLER ABRAHAM N. — SVP Corp Dev & Gen Counsel | Purchase (P): 2,381 @ $4.20 | EDGAR |
| 2021-09-29 | 4 | Gelder Mark S. MD — Chief Medical Officer | Purchase (P): 2,381 @ $4.20 | EDGAR |
| 2021-09-28 | 4 | Fruchtman Steven M — President, Chief Executive Off, Director | Purchase (P): 2,381 @ $4.20 | EDGAR |
| 2021-09-28 | 4 | MARINO JAMES J — Director | Purchase (P): 5,952 @ $4.20 | EDGAR |
| 2021-08-04 | 4 | Fruchtman Steven M — President, Chief Executive Off, Director | Grant/award (A): 113,000 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2021-08-04 | 4 | Gelder Mark S. MD — Chief Medical Officer | Grant/award (A): 41,825 (derivative) @ $0 · Grant/award (A): 13,950 (derivative) @ $0 | EDGAR |
| 2021-08-04 | 4 | Guerin Mark Patrick — Chief Financial Officer | Grant/award (A): 42,750 (derivative) @ $0 · Grant/award (A): 14,250 (derivative) @ $0 | EDGAR |
| 2021-08-04 | 4 | OLER ABRAHAM N. — SVP Corp Dev & Gen Counsel | Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 13,400 (derivative) @ $0 | EDGAR |
Recent 8-K events — Onconova Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-16 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-07-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Onconova Therapeutics, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299644 (S-1) — latest: Initial registration (S-1), filed 2026-10-26
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ONTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs